Cardiac Biomarkers: Technologies and Global Markets

Report Code: BIO128D

Publish Date: Mar 2023

Publisher: BCC Publishing

Category: Cell Biology

Download Report Overview

Single User License: $2500

Member Price: FREE

EXPLORE OFFERS

Explore Our Services

Already a member? Login to access this report free.

Report Highlights

The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.

Report Includes

  • 66 data tables and 36 additional tables
  • An up-to-date overview and analysis of the global markets for cardiac biomarkers technologies
  • Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for cardiac biomarkers market in USD million terms, and corresponding market share analysis based on the type of biomarker, instrument category, and region
  • Identification of the viable technology drivers and barriers through a holistic review of various platform technologies in cardiac biomarker measurement and their notable advancements
  • Complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications
  • Discussion of feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases
  • Emphasis on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth
  • Latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses
  • Review of the patents and patent applications on cardiac biomarkers and deep dive of recent global and region-specific patent publications related to cardiac biomarkers
  • Insight into the company competitive landscape and company value share analysis for the leading suppliers of cardiac biomarkers
  • Profile descriptions of the major global players, including Abbott Laboratories, Beckman Coulter (subsidiary of Danaher Corp.), bioMérieux S.A., PerkinElmer Inc., Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific Inc.

Report Scope

The scope of this report is:

  • Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
  • Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing and theragnostic, while also gaining an appreciation these elements from their basic principles to their applications.
  • Discover feasible market opportunities via the identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
  • Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
  • Present market figures for the current value of the cardiac biomarkers market, projections and growth rates. These are developed from the most recently available information from the global diagnostics industry.

By purchasing this study, the reader will gain:

  • An improved understanding of the current state and future of the most exciting cardiac biomarker market segments.
  • The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline.
  • Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment.

This analysis covers the following categories of the cardiac biomarker segments:

  • Acute Myocardial Infarction (AMI).
  • Heart failure.
  • Brain natriuretic peptide (BNP).
  • Myoglobin.
  • Homocysteine (Hcy).
  • C-reactive protein (CRP).
  • Pulmonary embolism (PE) D-dimer test.
  • Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
  • Stroke.
  • Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
  • Albumin.
  • Cardiac markers are used in clinical decisions.
  • Cardiac markers in renal failure.
  • Troponins in non-ischemic heart disease.
  • Cardiac panels.
  • POC cardiac markers.

Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study:

  • Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
  • Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
  • Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
  • Provides current and forecasted market shares by company.
  • Discusses profit and business opportunities by diagnostic testing segment.
  • Provides strategic recommendations for near-term business opportunities.
  • Assesses current commercial uses of the cardiac biomarker market.

Report Synopsis

Report Metrics Details
Base year considered 2021
Forecast period considered 2022-2027
Base year market size $11.9 billion
Market size forecast $23.8 billion
Growth rate CAGR of 12.2% for the forecast period of 2022-2027
Units considered $ Millions
Segments covered By Type of Biomarker, Instrument Category, and Region
Regions covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Countries covered U.S., Canada, France, Germany, Italy, Spain, U.K., Japan, China, India, South Korea, Australia, Rest of Europe, Rest of APAC
Key Market Drivers
  • Rising Prevalence of Cardiovascular Diseases (CVD)
  • Technological Advancements in Cardiac Biomarkers
  • Increased Funding from Public-Private Organizations for Research on Cardiac Biomarkers
  • Rising Demand for Point-of-Care (POC) Cardiac Testing Kits
  • High Specificity in the Detection of Cardiac Diseases
Companies studied
ABBOTTACS BIOMARKER BV
BECKMAN COULTER INC. (SUBSIDIARY OF DANAHER CORP.)BG MEDICINE INC.
BIOMERIEUXBIO-RAD LABORATORIES INC.
CARDIOGENICS INC.CREATIVE DIAGNOSTICS
CRITICAL DIAGNOSTICSLIFE DIAGNOSTICS
LIFESIGN LLCLSI MEDIENCE CORP.
MERIDIAN LIFE SCIENCE INC.METANOMICS HEALTH GMBH
ORTHO-CLINICAL DIAGNOSTICSPERKINELMER
PTS DIAGNOSTICSQUIDELORTHO CORP.
RADIOMETER MEDICAL APSRANDOX LABORATORIES LTD.
RESPONSE BIOMEDICAL CORP.F. HOFFMANN-LA ROCHE LTD.
SANYO CHEMICAL INDUSTRIES LTD.SIEMENS
SINGULEX INC.SPECTRAL MEDICAL INC.
THERMO FISHER SCIENTIFIC INC.TOSOH BIOSCIENCE INC.
TRINITY BIOTECH PLC
Need a custom data table, graph, region, segment, companies or complete report? CUSTOMIZE NOW

Frequently Asked Questions (FAQs)

The cardiac biomarkers market is projected to grow from $11.9 billion in 2021 to $23.8 billion in 2027, at a compound annual growth rate (CAGR) of 12.2% during the forecast period.
The key factors driving the growth of cardiac biomarkers market includes rising prevalence of cardiovascular diseases, technological advancements in cardiac biomarkers, rising demand for point-of-care (POC) cardiac testing kits, and high specificity in the detection of cardiac diseases.
The cardiac biomarkers market is segmented based on biomarker type, by instrument category, and region.
Troponin segment will dominate the market by the end of 2027.
North America holds the highest share in the market.
Key companies in the market includes Roche Laboratories, Abbott Laboratories, Siemens AG, Thermo Fisher Scientific, Beckman Coulter (Part of Danaher), Bio-Rad Laboratories, BioMérieux, Tosoh Bioscience, Ortho-Clinical Diagnostics, Quidel Corp., CardioGenics, Meridian Life Science, Sanyo Chemical Industries Ltd., Spectral Medical Inc., Trinity Biotech, and other key players.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.

Let us assist you! Our analysts are ready to tailor this report to your specific need. Talk to Our Analyst

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Cardiac Biomarkers: Technologies and Global Markets287Free
Chapter- 1: Introduction10Free
Chapter- 2: Summary and Highlights4Free
Chapter- 3: Cardiovascular Disease and Its Associated Burden31Free
Chapter- 4: Introduction to Cardiac Biomarkers35Free
Chapter- 5: Review of Key Individual Cardiac Biomarkers42Free
Chapter- 6: Global Market for Cardiac Biomarkers41Free
Chapter- 7: Impact of the COVID-19 Pandemic3Free
Chapter- 8: Regulatory and Legislative Requirements for Cardiac Biomarkers51Free
Chapter- 9: Patent Review and New Developments in Cardiac Biomarkers13Free
Chapter- 10: Competitive Landscape3Free
Chapter- 11: Company Profiles40Free
Chapter- 12: Appendix A: Company Addresses and Contact Details7Free
Chapter- 13: Appendix B: Government Regulatory Agencies and Professional Organizations2Free
Chapter- 14: Appendix C: Commonly Used Acronyms Associated with Cardiac Biomarkers5Free
Published - Jul-2018| Analyst - Paul Taylor| Code - BIO128C

Report Highlights

The global market for cardiac biomarker will grow from $6.3 billion in 2017 to $9.9 billion by 2022, at a compound annual growth rate (CAGR) of 9.5% for the period of 2017-2022

Report Includes

  • 64 data table and 40 additional tables
  • An overview of the global market for cardiac biomarkers and related technologies
  • Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT)
  • Examination of the technology regarding diagnostic methods, instrumentation, newly issued patents, and new patent applications
  • Coverage of clinical guidelines and government regulations
  • Comprehensive company profiles of major Players in the Market including Abbott Laboratories, Biomérieux S.A., Bio-Rad Laboratories Inc, Life Diagnostics Inc., Meridian Life Science Inc. Randox Laboratories Ltd., Roche, Sanyo Chemical Industries Ltd., Siemens Ag, and Thermo Fisher Scientific Inc.
Published - Jun-2016| Analyst - Anuj Pathak| Code - BIO128B

Report Highlights

The global cardiac biomarkers market has grown to $4.9 billion in 2015 from $4.4 billion in 2014. The market is expected to grow at a five-year compound annual growth rate (CAGR) of 12.4% from 2015 to 2020, increasing to over $8.8 billion in 2020.

Report Includes

  • An overview of the global market for cardiac biomarkers and related technologies.
  • Analyses of global market trends, with data from 2014, 2015, and projections of CAGRs through 2020.
  • Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
  • Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
  • Clinical guidelines and government regulations.
  • Profiles of major players in the industry.
Published - Mar-2014| Analyst - Cheng-Yuk Lee| Code - BIO128A

Report Highlights

The global market for in vitro diagnostic tests for cardiac biomarkers was estimated at $3.1 billion in 2012 and nearly $4 billion in 2013. This market is predicted to reach $7.2 billion by 2018, at a compound annual growth rate (CAGR) of 12.8% over the five-year period from 2013 to 2018.

Report Includes

  • An overview of the global market for biomarkers for cardiovascular disease (CVD) and related technologies.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of CAGRs for the period 2013 to 2018.
  • Classification of CVD by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease.
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT).
  • Examination of the technology covering diagnostic methods, instrumentation, newly issued patents, and new patent applications.
  • Clinical guidelines and government regulations.

Related Reports

Point-of-Care Diagnostics: Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC043H

The global market for point-of-care diagnostics was valued at $36.9 billion in 2023. It is expected to grow from $40.6 billion in 2024 to $65.9 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% from 2024 through 2029.

Companion Diagnostics: Technologies and Markets

Published - May 2024 | Publisher - BCC Publishing | Code - BIO077F

The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Published - Nov 2023 | Publisher - Bejini Sandeep Kumar | Code - PHM119C

The global market for antithrombotic/anticoagulant drugs is estimated to grow from $31.6 billion in 2023 to reach $46.2 billion by 2028, at a compound annual growth rate (CAGR) of 7.9% from 2023 through 2028.

Oncology Biomarkers: Global Markets

Published - Jul 2023 | Publisher - BCC Publishing | Code - BIO244A

The global oncology biomarkers market reached $15.5 billion in 2022, should reach $17.6 billion by 2023 and $35.2 billion by 2028 with a compound annual growth rate (CAGR) of 14.9% during the forecast period of 2023-2028.

Recent Reports

Global DNA Sequencing: Research, Applied and Clinical Markets

Published - Dec 2024 | Publisher - BCC Publishing | Code - BIO045J

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

Artificial Intelligence (AI) in Cancer

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO196B

The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Induced Pluripotent Stem Cells: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO135F

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 to 2028.

Top Trending Reports

Single-use Technologies for Biopharmaceuticals: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO099F

The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.

Cell and Gene Therapy Tools, and Reagents: Global Markets

Published - Nov 2024 | Publisher - BCC Publishing | Code - BIO208C

The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.

Global Market Opportunities and Competitive Landscape for CDMO

Published - Nov 2024 | Publisher - BCC Publishing | Code - PHM238B

The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

Published - Oct 2024 | Publisher - BCC Publishing | Code - HLC239C

The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.

Medical Devices Industry: Competitive Landscape

Published - Nov 2024 | Publisher - BCC Publishing | Code - MDS010C

The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Cardiac Biomarkers: Technologies and Global Markets
Sample Report